Neurocrine (NBIX) Q1 2026 earnings review
CRENESSITY Breaks Out, Soleno Buy Transforms Pipeline
Neurocrine delivered a transformative Q1. Net product sales surged 44% YoY to $811 million, obliterating historical growth rates thanks to CRENESSITY's explosive ramp ($153.3 million). The company is officially no longer a single-product story. Further validating this pivot, management announced a massive $2.9 billion cash acquisition of Soleno Therapeutics to secure VYKAT XR. However, beneath the headline beat, the legacy engine is stalling: INGREZZA sales were sequentially flat for the second straight quarter, as severe net pricing pressure completely neutralized double-digit volume growth.
🐂 Bull Case
In just one year on the market, CRENESSITY has scaled from $14.5M to $153.3M quarterly. It is rapidly becoming the standard of care for congenital adrenal hyperplasia, boasting 80% reimbursement rates.
The $2.9 billion Soleno acquisition buys immediate pipeline diversity and a first-in-class near-commercial asset (VYKAT XR) for Prader-Willi syndrome, leveraging Neurocrine's massive $2.6B cash pile.
🐻 Bear Case
Despite management touting 'record NRx' and 'double-digit volume growth,' INGREZZA revenue has decelerated and flatlined sequentially ($686M in 25Q3 -> $657M in 25Q4 -> $656M in 26Q1). The strategy to buy Medicare access via higher rebates is permanently impairing unit economics.
SG&A ballooned to $318.5M as the company heavily expanded sales forces for both commercial assets. If INGREZZA stalls further, these fixed costs will compress margins.
⚖️ Verdict: 🟢
Bullish. The flatlining of INGREZZA is a legitimate concern, but the sheer velocity of the CRENESSITY launch and the aggressive move to acquire Soleno Therapeutics prove that management successfully engineered the transition to a multi-franchise neuroscience powerhouse.
Key Themes
CRENESSITY Reaches Escape Velocity
Accelerating. CRENESSITY generated $153.3 million in Q1, up from $135.3 million in 25Q4. With approximately 80% reimbursement for dispensed prescriptions, access hurdles are largely cleared. The drug is performing flawlessly, carrying the entire company's YoY growth rate.
Strategic Pivot: The $2.9B Soleno Acquisition
Neurocrine is deploying its massive cash hoard to acquire Soleno Therapeutics for $53.00 per share. This adds VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome (PWS), a high-unmet-need rare disease. Expected to close in Q2 2026, this instantly expands the endocrinology portfolio and derisks the company's reliance on INGREZZA.
Data Contradiction: INGREZZA Volume vs. Revenue
Decelerating. Management claims 'double-digit prescription volume growth' and 'record NRx' for INGREZZA. However, the data contradicts the bullish narrative: Q1 revenue was $656.9M, effectively flat vs Q4 ($657.5M) and down significantly from Q3 ($686.6M). Management admits this is due to 'lower net price,' highlighting that the aggressive Medicare contracting strategy executed in 2025 is severely capping top-line expansion.
Runaway Operating Expenses
Accelerating. GAAP SG&A hit $318.5M (up 15% YoY) and GAAP R&D hit $296.2M (up 12% YoY). The SG&A surge is driven by aggressive sales force expansions for both INGREZZA and CRENESSITY. While justifiable during a launch phase, sequential creep in fixed costs requires constant monitoring.
Radical Profitability Reversal
Accelerating. Despite the massive expense base, top-line scale is driving incredible operating leverage. GAAP Operating Income hit $193.4M in 26Q1, a staggering reversal from just $23.6M in 25Q1. GAAP Net Income followed suit, jumping from $7.9M to $197.9M YoY.
Advancing the M1/M4 Muscarinic Franchise
Specific product progress: Neurocrine dosed the first patients in a Phase 2 study for NBI-1117570, a dual M1/M4 selective agonist for schizophrenia. This signals momentum in the highly competitive psychiatric space, building a deeper bench behind the Phase 3 direclidine asset.
Macro Headwinds: The IRA Ghost
While not explicitly named in the current press release, the continuous net price compression of INGREZZA is a direct fallout of the broader macro regulatory environment (Inflation Reduction Act). Neurocrine traded price for volume to secure Medicare Part D formulary positions ahead of looming Medicare negotiation dynamics, and the company is now paying the margin penalty.
Other KPIs
Stable sequential growth from $2.54 billion at year-end 2025. This fortress balance sheet allowed the company to comfortably announce the $2.9 billion all-cash acquisition of Soleno Therapeutics without raising dilutive equity.
Accelerating dramatically YoY from $71.5 million in 25Q1. This was heavily aided by higher total revenues and a $28.6 million pre-tax gain from the sale of Neurocrine Group Limited.
Guidance
Stable. The company reaffirmed its full-year guidance. Given Q1 sales of $656.9M, achieving the $2.75B midpoint requires an average of $697M over the next three quarters. This implies management expects a modest sequential acceleration in INGREZZA revenue later this year, likely banking on volume eventually outpacing the current pricing compression.
Accelerating compared to FY25 ($1.01B). Reflects heavy investment in late-stage Phase 3 programs like osavampator (MDD) and direclidine (schizophrenia), plus roughly $25 million in baked-in development milestones.
Accelerating compared to FY25 ($1.15B). The ~$225M step-up is driven by the annualized cost of expanding both the INGREZZA and CRENESSITY sales teams to push deeper into community prescriber networks.
Key Questions
INGREZZA Pricing Floor
With Q1 INGREZZA revenue essentially flat for the second quarter in a row despite double-digit volume growth, where is the floor for net price compression? When will volume gains finally translate back to meaningful sequential revenue growth?
Soleno Integration & Financial Impact
The Soleno acquisition costs $2.9 billion in cash. How will the integration of VYKAT XR alter the FY26 and FY27 operating expense trajectory, and when should investors expect it to become accretive to EPS?
CRENESSITY TAM Penetration
With $153.3M in Q1 sales, CRENESSITY is already annualizing over $600M. What percentage of the addressable classic CAH patient population does this currently represent, and are we approaching the slower 'community adoption' phase of the launch?